Biotech Values

[DewDiligence]

FDA grants priority review for Xarelto in ACS:

http://www.reuters.com/article/2012/02/27/jj-xarelto-idUSL4E8DRAC420120227

I’m a little surprised at the FDA’s decision here. The PDUFA date is in Jun 2012.

I previously opined—and continue to believe—that Xarelto will not take any significant market share from Lovenox in this indication (#msg-69172520).